$2.77
7.36% today
Nasdaq, Apr 04, 09:14 pm CET
ISIN
US2210151005
Symbol
CRVS
Sector
Industry

Corvus Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Corvus Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
100%

Corvus Pharmaceuticals, Inc. Price Target

Target Price $15.75
Price $2.99
Potential
Number of Estimates 4
4 Analysts have issued a price target Corvus Pharmaceuticals, Inc. 2026 . The average Corvus Pharmaceuticals, Inc. target price is $15.75. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 4 analysts: 4 Analysts recommend Corvus Pharmaceuticals, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Corvus Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Corvus Pharmaceuticals, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.02 -0.55
82.14% 46.08%
P/E negative

2 Analysts have issued a Corvus Pharmaceuticals, Inc. forecast for earnings per share. The average Corvus Pharmaceuticals, Inc. EPS is

$-0.55
Unlock
. This is
43.30% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.52 46.39%
Unlock
, the lowest is
$-0.57 41.24%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.02 82.14%
2025
$-0.55 46.08%
Unlock
2026
$0.20 136.36%
Unlock
2027
$0.17 15.00%
Unlock

P/E ratio

Current -3.09 1.90%
2025
-5.49 77.67%
Unlock
2026
14.95 372.31%
Unlock
2027
17.59 17.66%
Unlock

Current Corvus Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Mar 26 2025
Oppenheimer
Locked
Locked
Locked Mar 26 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 14 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 02 2025
Oppenheimer
Locked
Locked
Locked Nov 13 2024
Ladenburg Thalmann
Locked
Locked
Locked Sep 16 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 26 2025
Locked
Oppenheimer:
Locked
Locked
Mar 26 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 02 2025
Locked
Oppenheimer:
Locked
Locked
Nov 13 2024
Locked
Ladenburg Thalmann:
Locked
Locked
Sep 16 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today